The Use of Gastrografin in Chronic Radiation Enteropathy With Small Bowel Obstruction
- Registration Number
- NCT03642288
- Lead Sponsor
- Jinling Hospital, China
- Brief Summary
Chronic radiation enteropathy (CRE) is a major issue for long-term cancer survivors. The aim of this study was to clarify the diagnostic and therapeutic effect of the Gastrografin (GG) challenge for patients with CRE induced small bowel obstruction SBO.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 112
- with a first diagnosis of CRE combined with SBO and ASBO that was determined by clinical history, computed tomography (CT) manifestation, and confirmed by intraoperative and histologic findings.
- radiation therapy completed at least 6 months before enrolment.
- a colostomy or ileostomy;
- large bowel obstruction;
- with a known history of either allergy or hypersensitivity to iodinated contrast agents;
- with signs of strangulation;
- metastatic disease;
- obstruction within 4 weeks after a recent operation or serious comorbidity.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description CRE-induced SBO Gastrografin Patients with CRE-induced SBO received GG challenge. ASBO Gastrografin Patients with adhesive SBO (ASBO) received GG challenge.
- Primary Outcome Measures
Name Time Method The rate of successful conservative treatment 5 days The rate of patients who need for operative intervention within 48 hours of randomization.
- Secondary Outcome Measures
Name Time Method The time to resolution 2 weeks The time to resolution of ASIO (flatus and bowel motion).
The length of hospital stays 2 weeks The length of hospital stays (in hours, calculated from the hospital admission to resolution of intestinal obstruction).
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.